Lustgewinn Viagra for women receives approval in the US

Viagra for women ": Flibanserin approved in the US
From October may be sold in the US, a kind of "Viagra for women". The Food and Drug Administration (FDA) gave the green light to the drug Flibanserin, which will be launched under the name "Addyi". The remedy is intended to increase female pleasure. The effectiveness is controversial.

Pill is designed to increase sexual pleasure
On Tuesday, the Food and Drug Administration in Washington gave the go-ahead for the drug flibanserin. From October, the "Viagra for women" may be sold in the US. The product, which is known as "Pink Viagra" because of its color, comes under the name "Addyi" on the market. It aims to increase the sexual desire of women. Unlike the drug for men, which tackles a physical problem, Flibanserin should affect the psyche. However, the pill's efficiency is controversial.

Does not work physically stimulating
For the first time, the FDA has approved an add-on drug as a drug. The approval was preceded by a year-long dispute that sparked the effectiveness and safety of the pink pill. The remedy is intended to arouse the sexual desire of women, but is not a physical stimulant. News agency AFP reports, FDA drug testing center head Janet Woodcock said, "Today's approval grants women who are suffering from sexual disability a viable treatment option." And further, "The FDA is concerned with protection and promotion women's health and we are committed to supporting the development of safe and effective drugs. "

Drug must be taken daily
The drug is said to be specifically approved for the treatment of general hypoactive sexual desire disorder (HSDD) in premenopausal women. It is taken daily and not just before sexual intercourse. According to the FDA, the remedy is expressly not applicable if the diminished sex drive is due to mental or physical discomfort, relationship issues, or the influence of medication or other drugs. The packaging warns that the drug in combination with alcohol can lead to dangerously low blood pressure and fainting. Such health problems are also possible if the pink pill, for example, be taken with anti-fungal agents. "Patients and prescribers should fully understand the risks associated with taking Addyi before considering treatment," warned Woodcock.

Suitable for only a few women
Flibanserin acts via the brain, it should lower the level of the pleasure-suppressing hormone serotonin and at the same time stimulate the concentration of the happiness hormone dopamine and the stimulating hormone norepinephrine in the blood. According to FDA publications, women taking the drug had sex half to one sex a month more than women taking placebo. Although this is a low value, make a lot of difference for many women or couples. According to medical experts, about every third woman in Germany has libido disorders. Causes can include stress, overwork, habit and physical suffering. Health experts say the drug can help less than ten percent of women.

No application for approval in Europe
Whether Flibanserin could exist in Germany is still unclear. As a spokeswoman for the German licensing authority, the Federal Institute for Drugs and Medical Devices (BfArM) announced in June, they have not yet submitted an application. At the time, according to a spokeswoman, there was no application for the European Medicines Agency EMA. In the US, the drug was twice rejected by the FDA. This triggered fierce protests by women's rights groups in the US. These accused the authority sexism, since they have allowed Viagra, but not Flibanserin. Other groups claimed that the company was abusing the activists to push through a drug that had not yet been proven safe.

Funds was developed in Germany
Flibanserin was originally developed by the German manufacturer Boehringer Ingelheim as a remedy for depression. After a negative FDA report, the company abandoned the project and in 2010, Sprout Pharmaceuticals of Raleigh, North Carolina took over the research that has now led to its success. Low efficiency or adverse effects were reported early. Years ago, studies indicated that women who took the drug had only a modest upward trend in their "sexually satisfying events". Also on the frequently occurring side effects has been reported. Research has shown that women experience symptoms such as dizziness, fatigue and nausea, and occasionally insomnia, dry mouth and constipation. (Ad)